Using spectroscopic and microscopic methods to probe the structural stability of human adenovirus type 4

Human Vaccines

Volumn 6, Issue 2, 2010, Pages 202-211

  He, Feng ^a,c   Joshi, Sangeeta B ^a   Moore, David S ^a   Shinogle, Heather E ^a   Ohtake, Satoshi ^b   Lechuga Ballesteros, David ^b   Martin, Russell A ^b   Truong Le, Vu L ^b   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b Aridis Pharmaceuticals LLC   (United States)

^c AMGEN INC   (United States)

Author keywords

Absorption spectroscopy; Adenovirus; Circular dichroism; Dynamic light scattering; Fluorescence spectroscopy; Stability; Transmission electron microscopy

Indexed keywords

TRYPTOPHAN; VIRUS PROTEIN;

ARTICLE; CIRCULAR DICHROISM; FLUORESCENCE SPECTROSCOPY; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS 2; HUMAN ADENOVIRUS 4; HUMAN ADENOVIRUS 5; LIGHT SCATTERING; NONHUMAN; OPTICAL DENSITY; PH; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; TEMPERATURE STRESS; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; VIRION; VIRUS MORPHOLOGY;

ADENOVIRIDAE; CIRCULAR DICHROISM; HOT TEMPERATURE; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, TRANSMISSION; PROTEIN STABILITY; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, FLUORESCENCE; SPECTROPHOTOMETRY, ULTRAVIOLET; TRYPTOPHAN; VIRAL PROTEINS; VIRION;

EID: 77953642224     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.2.10254     Document Type: Article

References (41)

1. Hayashi S, Hogg JC. Adenovirus infections and lung disease. Curr Opin Pharmacol 2007; 7:237-43.
2. Lenaerts L, Naesens L. Antiviral therapy for adenovirus infections. Antiviral Res 2006; 71:172-80.
3. Krilov LR. Adenovirus infections in the immunocompromised host. Pediatr Infect Dis J 2005; 24:555-6.
4. Leen AM, Rooney CM. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol 2005; 128:135-44.
5. Hilleman MR, Werner JH. Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 1954; 85:183-8.
6. Stewart PL, Burnett RM. Adenovirus structure by X-ray crystallography and electron microscopy. Curr Top Microbiol Immunol 1995; 199:25-38.
7. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 1999; 11:380-6.
8. Burnett RM. The structure of the adenovirus capsid II. The packing symmetry of hexon and its implications for viral architecture. J Mol Biol 1985; 185:125-43.
9. Burnett RM, Grutter MG, White JL. The structure of the adenovirus capsid I. An envelope model of hexon at 6 A resolution. J Mol Biol 1985; 185:105-23.
10. Cusack S. Adenovirus complex structures. Curr Opin Struct Biol 2005; 15:237-43.
11. Metzgar D, Osuna M, Kajon AE, Hawksworth AW, Irvine M, Russell KL. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J Infect Dis 2007; 196:1465-73.
12. Zhou D, Ertl HC. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opin Biol Ther 2006; 6:63-72.
13. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006; 2:137-43.
14. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81:2573-604.
15. Shashkova EV, Kuppuswamy MN, Wold WS, Doronin K. Anticancer activity of oncolytic adenovirus vector armed with IFNalpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther 2008; 15:61-72.
16. Xing Z, Santosuosso M, McCormick S, Yang TC, Millar J, Hitt M, et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther 2005; 5:485-92.
17. Chanda PK, Natuk RJ, Dheer SK, Lubeck MD, Bhat BM, Mason BB, et al. Helper independent recombinant adenovirus vectors: expression of HIV env or HBV surface antigen. Int Rev Immunol 1990; 7:67-77.
18. Hung PP, Chanda PK, Natuk RJ, Mason BB, Chengalvala M, Bhat BM, et al. Adenovirus vaccine strains genetically engineered to express HIV-1 or HBV antigens for use as live recombinant vaccines. Nat Immun Cell Growth Regul 1990; 9:160-4.
19. Wu Q, Xia D, Carlsen S, Xiang J. Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer. Curr Gene Ther 2005; 5:237-47.
20. Levandowski RA, Rubenis M. Nosocomial conjunctivitis caused by adenovirus type 4. J Infect Dis 1981; 143:28-31.
21. Kajon AE, Moseley JM, Metzgar D, Huong HS, Wadleigh A, Ryan MA, et al. Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997-2003). J Infect Dis 2007; 196:67-75.
22. Sanford JP. Acute respiratory disease in the United States Army in the Republic of Vietnam, 1965-1970. Yale J Biol Med 1975; 48:179-84.
23. Ausar SF, Espina M, Brock J, Thyagarayapuran N, Repetto R, Khandke L, et al. High-throughput screening of stabilizers for respiratory syncytial virus: identification of stabilizers and their effects on the conformational thermostability of viral particles. Hum Vaccin 2007; 3:94-103.
24. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem 2006; 281:19478-88.
25. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2005; 2:491-9.
26. Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, et al. Physical stabilization of Norwalk virus-like particles. J Pharm Sci 2008; 97:4208-18.
27. Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, et al. Stabilization of measles virus for vaccine formulation. Hum Vaccin 2008; 4:350-9.
28. Rexroad J, Wiethoff CM, Green AP, Kierstead TD, Scott MO, Middaugh CR. Structural stability of adenovirus type 5. J Pharm Sci 2003; 92:665-78.
29. Rexroad J, Evans RK, Middaugh CR. Effect of pH and ionic strength on the physical stability of adenovirus type 5. J Pharm Sci 2006; 95:237-47.
30. Rexroad J, Martin TT, McNeilly D, Godwin S, Middaugh CR. Thermal stability of adenovirus type 2 as a function of pH. J Pharm Sci 2006; 95:1469-79.
31. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci 2003; 92:1805-20.
32. Salnikova MS, Joshi SB, Rytting JH, Warny M, Middaugh CR. Preformulation studies of Clostridium difficile toxoids A and B. J Pharm Sci 2008; 97:4194-207.
33. Ruponen M, Braun CS, Middaugh CR. Biophysical characterization of polymeric and liposomal gene delivery systems using empirical phase diagrams. J Pharm Sci 2006; 95:2101-14.
34. Altaras NE, Aunins JG, Evans RK, Kamen A, Konz JO, Wolf JJ. Production and formulation of adenovirus vectors. Adv Biochem Eng Biotechnol 2005; 99:193-260.
35. Galdiero F. Adenovirus aggregation and preservation in extracellular environment. Arch Virol 1979; 59:99-105.
36. Athappilly FK, Murali R, Rux JJ, Cai Z, Burnett RM. The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J Mol Biol 1994; 242:430-55.
37. Fuschiotti P, Fender P, Schoehn G, Conway JF. Development of the dodecahedral penton particle from adenovirus 3 for therapeutic application. J Gen Virol 2006; 87:2901-5.
38. Hartman ZC, Appledorn DM, Serra D, Glass O, Mendelson TB, Clay TM, Amalfitano A. Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology 2008; 374:453-67.
39. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 2008; 132:1-14.
40. Stewart PL, Burnett RM, Cyrklaff M, Fuller SD. Image reconstruction reveals the complex molecular organization of adenovirus. Cell 1991; 67:145-54. (Pubitemid 121001431)
41. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.